Tissue Doppler Ultrasound During Spontaneous Breathing and Non-invasive Ventilation in the Post-extubation Period. (TDIpostext)

July 21, 2019 updated by: Gianmaria Cammarota, Azienda Ospedaliero Universitaria Maggiore della Carita

Diaphragm Performance Evaluation With Tissue Doppler Ultrasound Examination During Spontaneous Breathing in Facial Mask and During Non-invasive Ventilation in the Post-extubation Period.

The aim of the present investigation will be to evaluate diaphragmatic excursion velocity during non-invasive ventilation and spontaneous breathing at both inspiration and expiration.

this analysis will be performed through diaphragmatic tissue Doppler assessment.

Study Overview

Status

Unknown

Intervention / Treatment

Detailed Description

Early weaning from invasive ventilation, in patients admitted to intensive care, is associated with a marked reduction in ventilator-associated pneumonia, length of stay in intensive care unit and hospital, total duration of mechanical ventilation and decrease in overall mortality. Moreover, in case of need of protected extubation, non-invasive ventilation has allowed to prevent re-intubation and decrease hospital mortality compared to the simple administration of oxygen through a facial mask, in particular when applied immediately after extubation.

The diaphragmatic tissue doppler imaging (TDI) is an ultrasonographic technique derived from ultrasound evaluation of the heart's motility. It can be easily used on the diaphragm to calculate the speed of muscles displacement that could be associated with patient's respiratory drive.

The aim of the study is the evaluation of the diaphragmatic excursion velocity variations using diaphragmatic tissue doppler, measured in venturi mask and non-invasive ventilation in the post-extubation period, in order to compare the diaphragm stress variations during the two different modes.

Method Patients after extubation will be randomly submitted to a spontaneous breathing test in venturi mask and in facemask or helmet NIV.

Each trial will last 20 minutes. During the last minute of each trial a tissue doppler diaphragm examination will be performed to assess the speed speed of muscle displacement, acceleration and deceleration.

Inclusion criteria: invasive mechanical ventilation > 24h with consequent extubation.

Exclusion criteria: refusal to grant consent, pregnancy, age < 18 years, haemodynamic instability, difficult management of secretions, required inotropic and / or vasoactive drugs at high doses.

During the study, vital parameters will be given.

Study Type

Interventional

Enrollment (Anticipated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Gianmaria Cammarota, MD,PHD
  • Phone Number: 00393392669420
  • Email: gmcamma@gmail.com

Study Contact Backup

  • Name: Gianmaria MD Cammarota
  • Phone Number: 00393392669420

Study Locations

      • Novara, Italy, 28100
        • Recruiting
        • A.O.U Maggiore della Carità
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • invasive mechanical ventilation > 24h with consequent extubation

Exclusion Criteria:

  • refusal to grant consent
  • pregnancy
  • age >18 years
  • haemodynamic instability
  • difficult management of secretions
  • required inotropic and / or vasoactive drugs at high doses

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: diaphragmatic tissue doppler evaluation
A tissue Doppler evaluation, using a sectorial probe, will be performed by analyzing the diaphragmatic displacement velocity during inspiration and expiration randomly assessed in spontaneous breathing with Venturi Mask and in Non-invasive ventilation with a helmet or facial mask
A diaphragmatic tissue Doppler evaluation will be performed during non-invasive ventilation and spontaneous breathing trial applied in random sequence. Each trial will last 20 minutes. During the last minute of each trial a tissue doppler diaphragmatic examination will be performed to assess the speed of diaphragmatic displacement during inspiration and expiration.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
diaphragmatic displacement velocity
Time Frame: through each trial completion, an average of 20 minutes
Inspiratory and expiratory diaphragmatic displacement velocity evaluated with tissue doppler during the NIV trial and in spontaneous breathing with Venturi mask.
through each trial completion, an average of 20 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diaphragmatic acceleration
Time Frame: through each trial completion, an average of 20 minutes
Inspiratory and expiratory diaphragmatic displacement acceleration evaluated with tissue doppler during the NIV trial and in spontaneous breathing with Venturi mask.
through each trial completion, an average of 20 minutes
Gas exchange - arterial carbon dioxide tension
Time Frame: through each trial completion, an average of 20 minutes
PaCO2, will be obtained performing ABG sample
through each trial completion, an average of 20 minutes
Gas exchange - pH
Time Frame: through each trial completion, an average of 20 minutes
pH will be obtained performing ABGs.
through each trial completion, an average of 20 minutes
Gas exchange - arterial oxygen tension
Time Frame: through each trial completion, an average of 20 minutes
arterial oxygenation PaO2 will be obtained performing ABGs.
through each trial completion, an average of 20 minutes
Dyspnea level
Time Frame: through each trial completion, an average of 20 minutes
dyspnea level evaluated through visual analogical scale ( VAS dyspnea)
through each trial completion, an average of 20 minutes
Comfort level
Time Frame: through each trial completion, an average of 20 minutes
Comfort level evaluated through Comfort Scale
through each trial completion, an average of 20 minutes
Hemodynamic parameters, Heart Rate (HR)
Time Frame: athrough each trial completion, an average of 20 minutes
Heart Rate (HR)
athrough each trial completion, an average of 20 minutes
Blood Pressure (BP)
Time Frame: through each trial completion, an average of 20 minutes
invasive Mean arterial Blood Pressure
through each trial completion, an average of 20 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

April 1, 2019

Primary Completion (ANTICIPATED)

December 12, 2019

Study Completion (ANTICIPATED)

April 1, 2020

Study Registration Dates

First Submitted

May 13, 2019

First Submitted That Met QC Criteria

June 4, 2019

First Posted (ACTUAL)

June 7, 2019

Study Record Updates

Last Update Posted (ACTUAL)

July 23, 2019

Last Update Submitted That Met QC Criteria

July 21, 2019

Last Verified

May 1, 2019

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Respiratory Failure

Clinical Trials on Post-extubation TDI

3
Subscribe